Seminars in Oncology Nursing
Volume 23 , Pages 36-43 , February 2007

Case Studies in Metastatic Colorectal Cancer

References 

  1. Benson A, Ajain A, Catalano R, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–2926
  2. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  3. Eloxatin prescribing information. Bridgewater, NJ: Sanofi-Aventis; 2005;April. Available at: www.eloxatin.com (accessed July 9, 2006)
  4. Wilkes G. Therapeutic options in the management of colon cancer: 2005 update. J Clin Oncol. 2005;9:31–44
  5. Yamamoto D, Viale P, Roessner K, et al. The clinical use of tumor markers in select cancers: Are you confident enough to discuss them with your patients?. Oncol Nurs Forum. 2005;32:1013–1022
  6. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20:1759–1766
  7. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–2091
  8. Berry SR, Cunningham D, Michael M, et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC–First B.E.A.Trial. [abstr 3534] Proc Am Soc Clin Oncol. 2006;24:154s
  9. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer (Recent advances in management). Oncology. 2005;19(suppl 6):11–17
  10. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstr 3508]. Proc Am Soc Clin Oncol. 2005;23:348s
  11. Cunningham D, Humblet Y, Sienna S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345

PII: S0749-2081(06)00114-8

doi: 10.1016/j.soncn.2006.08.004

Seminars in Oncology Nursing
Volume 23 , Pages 36-43 , February 2007

Article Tools